Shanghai Pharma reports strong Q3 profit growth, driven by one-off gains

For the first nine months of 2025, Shanghai Pharmaceuticals Holding Co., Ltd. reported a total operating income of 215.072 bn yuan, a 2.60% year-on-year increase. Pharmaceutical services revenue grew by 2.91% to 196.908 bn yuan, while pharmaceutical manufacturing revenue saw a slight decrease of 0.66% to 18.164 bn yuan.

Net profit attributable to shareholders of the listed company surged by 26.96% year-on-year to 5.147 bn yuan. This growth was primarily attributed to one-off special gains from an accounting change for Hutchison Pharmaceuticals. Excluding these special gains, net profit attributable to parent company shareholders decreased by 1.85% to 3.979 bn yuan. The company maintained high-quality development with an operating net cash inflow of 2.350 bn yuan.

Shanghai Pharmaceuticals invested 1.729 bn yuan in R&D, representing 9.52% of pharmaceutical manufacturing sales revenue. As of the end of the reporting period, 57 new drug pipelines were in clinical trial application or clinical trial stages, including 45 innovative drug pipelines.